For its fourth fiscal quarter (ending June 30), Bio-Techne Corp (NASDAQ: TECH) has reported a -46% decline in E.P.S. from $0.48 a year ago to $0.26 in the current quarter. This result fell short of the consensus estimate of $0.50 by $-0.23. For the latest four quarters through June 30, E.P.S. were $1.07 versus $1.81 for the same period a year ago — a decline of -41%.
Recent Price Action
Bio-Techne Corp (NASDAQ: TECH) stock suffered a large decline of -9.5% on 8/7/24. The stock closed at $70.96. Moreover, exceptionally high trading volume at 248% of normal accompanied the decline. The stock has been strong relative to the market over the last nine months but has declined -13.4% during the last week.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to exceed the cost of capital, TECH is expected to continue to be an important Value Builder.
Bio-Techne has a current Value Trend Rating of D (Negative). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing contradictory signals. Bio-Techne has a poor Appreciation Score of 18 but a slightly positive Power Rating of 64, with the Negative Value Trend Rating the result.
Rating Review
In light of this new information we are reviewing our current Overall Rating of D. This review will be completed in the next several days.
Be the first to comment